The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis
| Autor: | Yong-Ping Chen, Lanman Xu, Jin-Lu Wu, Hui Li, Da-Zhi Chen, Lu Chen, Feng-Bin Lu, En-De Hu |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Adult medicine.medical_specialty Time Factors Disease Gastroenterology Severity of Illness Index 03 medical and health sciences Liver disease 0302 clinical medicine Non-alcoholic Fatty Liver Disease Risk Factors Internal medicine Nonalcoholic fatty liver disease Odds Ratio Medicine Humans Genetic Predisposition to Disease Obesity Aged Polymorphism Genetic Hepatology business.industry Fatty liver Membrane Proteins Odds ratio Lipase Middle Aged medicine.disease Prognosis 030104 developmental biology Phenotype Meta-analysis Disease Progression 030211 gastroenterology & hepatology Liver function Metabolic syndrome business |
| Zdroj: | Expert review of gastroenterologyhepatology. 12(5) |
| ISSN: | 1747-4132 |
| Popis: | A number of researches have explored the association between obesity and nonalcoholic fatty liver disease (NAFLD) liver function, histopathology, complications, genetic factors and prognosis, but the results were conflicting and inconclusive. Areas covered: In this meta-analysis, the liver function, histopathology, metabolic complications, patatin-like phospholipase domain-containing protein 3 (PNPLA3) genetic polymorphism and prognosis were compared between non-obese and obese NAFLD. Pubmed, EMBASE, Cochrane databases were searched to identify eligible studies. The odds ratio (OR) or standardized mean difference (SMD) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models. Expert commentary: This meta-analysis indicated that for NAFLD patients, obesity (according to ethnic-specific BMI cut-off points to define obesity) could predict a worse long-term prognosis. However, obesity may not be an independent factor for the development of NASH or advanced fibrosis in NAFLD patients and NAFLD should be considered as potential population for pharmacologic treatment regardless of obesity. In addition, PNPLA3 rs738409 may be more relevant to the progression of non-obese NAFLD when compared to obese NAFLD. Importantly, large-sample, long-term follow-up cohort studies based on liver biopsy are highly needed due to limited liver pathology and long-term follow-up data at present. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|